4'-acetamido-2-hydroxyacetophenone | 501696-51-1

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 4'-acetamido-2-hydroxyacetophenone
• 英文别名: N-(4-(2-hydroxyacetyl)phenyl)acetamide；acetic acid-(4-glycoloyl-anilide)；Essigsaeure-(4-glykoloyl-anilid)；4-Acetamino-ω-oxy-acetophenon；4-Acetamino-phenacylalkohol；N-[4-(2-hydroxyacetyl)phenyl]acetamide
• CAS: 501696-51-1
• 化学式: C₁₀H₁₁NO₃
• 分子量: 193.202
• InChiKey: BRWJYIYOWLWOPN-UHFFFAOYSA-N

物化性质

• 熔点：
  176 °C
• 沸点：
  452.5±25.0 °C(Predicted)
• 密度：
  1.274±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  66.4
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4'-acetamido-2-hydroxyacetophenone 在 氨 、 乙酸酐 、 二乙胺 作用下， 以 四氢呋喃 、 乙醇 、 N,N-二甲基甲酰胺 为溶剂， 生成
  参考文献：
  名称：

  Orally active 4-amino-5-diarylurea-furo[2,3-d]pyrimidine derivatives as anti-angiogenic agent inhibiting VEGFR2 and Tie-2

  摘要：

  During our effort to develop dual VEGFR2 and Tie-2 inhibitors as anti-angiogenic agents for cancer therapy, we discovered 4-amino-5-(4-((2-fluoro-5-(trifluoromethyl)phenyl)-aminocarbonylamino)phenyl)furo[2,3-d]pyrimidine (8a) possessing strong inhibitory activity at both the enzyme and cellular level against VEGFR2 and Tie-2. Compound 8a demonstrated high pharmaco-kinetic exposure through oral administration, and showed marked tumor growth inhibition and anti-angiogenic activity in mouse HT-29 xenograft model via once-daily oral administration. (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2006.12.077
• 作为产物：
  描述：

  4-乙酰胺苯乙酮 在 溴 、 potassium formate 、 碳酸氢钠 、 溶剂黄146 作用下， 以 乙醇 、 水 为溶剂， 生成 4'-acetamido-2-hydroxyacetophenone
  参考文献：
  名称：

  Orally active 4-amino-5-diarylurea-furo[2,3-d]pyrimidine derivatives as anti-angiogenic agent inhibiting VEGFR2 and Tie-2

  摘要：

  During our effort to develop dual VEGFR2 and Tie-2 inhibitors as anti-angiogenic agents for cancer therapy, we discovered 4-amino-5-(4-((2-fluoro-5-(trifluoromethyl)phenyl)-aminocarbonylamino)phenyl)furo[2,3-d]pyrimidine (8a) possessing strong inhibitory activity at both the enzyme and cellular level against VEGFR2 and Tie-2. Compound 8a demonstrated high pharmaco-kinetic exposure through oral administration, and showed marked tumor growth inhibition and anti-angiogenic activity in mouse HT-29 xenograft model via once-daily oral administration. (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2006.12.077

文献信息

• Aerobic Direct Dioxygenation of Terminal/Internal Alkynes to α‐Hydroxyketones by an Fe Porphyrin Catalyst
  作者：Kento Kimura、Takuya Kurahashi、Seijiro Matsubara

  DOI：10.1002/asia.202101019

  日期：2021.11.15

  The synthesis of α-hydroxyketones through the dioxygenation of alkynes is reported. The reaction is mediated by an Fe porphyrin complex and pinacolborane at room temperature under air as a green oxidant, furnishing α-hydroxyketones in up to 93% yields. The mild reaction conditions allow chemoselective oxidation with good functional group tolerance.

  报道了通过炔烃的双氧合合成 α-羟基酮。该反应由铁卟啉配合物和频哪醇硼烷在室温下作为绿色氧化剂介导，以高达 93% 的产率提供 α-羟基酮。温和的反应条件允许具有良好官能团耐受性的化学选择性氧化。
• Chroman derivatives as 5-hydroxytrytamine-6 ligands
  申请人：Wyeth

  公开号：US20030158175A1

  公开（公告）日：2003-08-21

  The present invention provides a compound of formula I and the use thereof for the therapeutic treatment of disorders relating to or affected by the 5-HT6 receptor. 1

  本发明提供了一种I式化合物及其用于治疗与5-HT6受体相关或受其影响的疾病的用途。
• Antidepressant azaheterocyclylmethyl derivatives of 7,8-dihydro-6H-5-oxa-1-aza-phenanthrene
  申请人：Wyeth

  公开号：US20030078268A1

  公开（公告）日：2003-04-24

  Compounds of the formula 1 useful for the treatment of such as depression (including but not limited to major depressive disorder, childhood depression and dysthymia), anxiety, panic disorder, post-traumatic stress disorder, premenstrual dysphoric disorder (also known as pre-menstrual syndrome), attention deficit disorder (with and without hyperactivity), obsessive compulsive disorder (including trichotillomania), social anxiety disorder, generalized anxiety disorder, obesity, eating disorders such as anorexia nervosa, bulimia nervosa, vasomotor flushing, cocaine and alcohol addition, sexual dysfunction (including premature ejaculation), and related illnesses.

  该公式的化合物用于治疗抑郁症（包括但不限于重性抑郁障碍、儿童抑郁症和心境低落障碍）、焦虑、恐慌障碍、创伤后应激障碍、经前期失调性障碍（也称为经前综合征）、注意力缺陷障碍（伴有和不伴有多动症）、强迫症（包括拔毛症）、社交焦虑障碍、广泛性焦虑障碍、肥胖、饮食失调如厌食症、暴食症、血管运动性潮红、可卡因和酒精成瘾、性功能障碍（包括早泄）及相关疾病。
• p-Hydroxyphenacyl ATP1: A new phototrigger
  作者：Richard S. Givens、Chan-Ho Park

  DOI：10.1016/0040-4039(96)01390-1

  日期：1996.8

  A new photoactivated “caged” ATP, p-hydroxyphenacyl ATP (4), is introduced to replace the o-nitrophenethyl and desyl analogues as a more efficient, rapid release phototrigger for ATP.

  引入了一种新的光活化的“笼中” ATP，对羟基苯甲酰基ATP（4），以取代邻硝基苯乙基和desyl类似物，从而更有效，快速释放ATP的光触发。
• Antidepressant azaheterocyclyl methyl derivatives of 7,8-dihydro-6H-5-oxa-1-aza-phenanthrene
  申请人：WYETH

  公开号：US20040235851A1

  公开（公告）日：2004-11-25

  Compounds of the formula 1 useful for the treatment of such as depression (including but not limited to major depressive disorder, childhood depression and dysthymia), anxiety, panic disorder, post-traumatic stress disorder, premenstrual dysphoric disorder (also known as pre-menstrual syndrome), attention deficit disorder (with and without hyperactivity), obsessive compulsive disorder (including trichotillomania), social anxiety disorder, generalized anxiety disorder, obesity, eating disorders such as anorexia nervosa, bulimia nervosa, vasomotor flushing, cocaine and alcohol addition, sexual dysfunction (including premature ejaculation), and related illnesses.

  公式为1的化合物，可用于治疗抑郁症（包括但不限于重度抑郁障碍、儿童抑郁症和慢性抑郁症）、焦虑症、惊恐障碍、创伤后应激障碍、经前期不良情绪障碍（也称为经前综合症）、注意力缺陷障碍（伴有或不伴有多动症）、强迫症（包括拔毛症）、社交焦虑障碍、广泛性焦虑障碍、肥胖症、饮食失调（如厌食症、贪食症）、潮红、可卡因和酒精成瘾、性功能障碍（包括早泄）及相关疾病的治疗。